



MEDICAL TIPS

BLUGLIP TABLETS

Issue V, No. 18, 2022

Drivers of vildagliptin prescription for Romanian patients with type 2 diabetes, the TREND study

Timar B et al. Romanian J of Diabetes Nutrition & Metabolic Disease 2022; 29(1): 83-91.

- Vildagliptin is associated with a slightly better reductions in HbA1c levels even in adjusted dosage irrespective of eGFR.
- In a cross-sectional, non-interventional study, data from 1918 patients considering vildagliptin was collected by diabetologists.
- The majority of Vildagliptin's associations were to prior Metformin treatment (83.6%), among who in 48.7% of the cases Vildagliptin was added as early as possible.
- The most important driver for considering Vildagliptin was the improvement of glycemic control (72.6%), followed by CV protection (65.5%), avoiding hypoglycemia (61.9%) and the possibility of safe use in chronic kidney disease (59.1%).

The most important factor in considering Vildagliptin for a patient is the improvement of the glycemic control, excellent safety profile and possibility to use irrespective of eGFR.

